Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: Case-crossover study

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 4, 2015, Pages 414-426

  Gillespie, Iain A ^a   Macdougall, I C ^b   Richards, Sharon ^a   Jones, Vincent ^a   Marcelli, Daniele ^c   Froissart, Marc ^d   Eckardt, K U ^e   Aljama, P ^f   Anker, S ^g   Canaud, B ^h   Drueke, T B ⁱ   Floege, J ^j   de Francisco, A ^k   Kronenberg, F ^l   Schernthaner, G ^m   Stenvinkel, P ⁿ   Wheeler, D C ^o   Fouqueray, B ^d   Molemans, B ^d   Roddam, A W ^a  

^a AMGEN LTD   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c FRESENIUS MEDICAL CARE   (Germany)

^d AMGEN INC   (United States)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^h LAPEYRONIE HOSPITAL   (France)

ⁱ UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^j RWTH AACHEN UNIVERSITY   (Germany)

^k HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^l INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^m KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Anaemia; CKD; Erythropoietin; Europe; Haemodialysis; Hyporesponsiveness; Pharmacoepidemiology

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

ANEMIA; ARTICLE; CATHETERIZATION; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CROSSOVER PROCEDURE; FEMALE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT RESPONSE; VASCULAR ACCESS; DOSE RESPONSE; EUROPE; MULTIVARIATE ANALYSIS; RISK FACTOR; STATISTICAL MODEL;

ANEMIA; COHORT STUDIES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; HEMATINICS; HUMANS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; RENAL DIALYSIS; RISK FACTORS;

EID: 84925944451     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3755     Document Type: Article

References (50)

1. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006; 368: 947-953.
2. Koury MJ. Erythropoietin: the story of hypoxia and a finely regulated hematopoietic hormone. Exp Hematol 2005; 33: 1263-1270.
3. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162: 1401-1408.
4. Mercadal L, Metzger M, Casadevall N, et al. Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol 2012; 7: 35-42.
5. Akmal M, Sawelson S, Karubian F, Gadallah M. The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 1994; 42: 198-202.
6. Eschbach JW, Jr, Funk D, Adamson J, Kuhn I, Scribner BH, Finch CA. Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 1967; 276: 653-658.
7. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis 2004; 44: 715-719.
8. Kovesdy CP, Kalantar-Zadeh K. Iron therapy in chronic kidney disease: current controversies. J Ren Care 2009; 35(Suppl 2): 14-24.
9. Besarab A, Yee J. Candidate biomarkers for erythropoietin response in end-stage renal disease. Kidney Int 2011; 79: 488-490.
10. Bradbury BD, Danese MD, Gleeson M, Critchlow CW. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11g/dL. Clin J Am Soc Nephrol 2009; 4: 630-637.
11. Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083.
12. Szczech LA, Barnhart HX, Sapp S, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 2010; 77: 239-246.
13. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146-1155.
14. Kaysen GA, Muller HG, Ding J, Chertow GM. Challenging the validity of the EPO index. Am J Kidney Dis 2006; 47: 166.
15. Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl 2008: S75-S81. doi:10.1038/ki.2008.523.
16. Panichi V, Rosati A, Bigazzi R, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011; 26: 2641-2648.
17. Fukuma S, Yamaguchi T, Hashimoto S, et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis 2012; 59: 108-116.
18. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538.
19. Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16: 1416-1423.
20. Goicoechea M, Caramelo C, Rodriguez P, et al. Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis. Nephrol Dial Transplant 2001; 16: 2188-2193.
21. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 2002; 17(Suppl 1): 53-59.
22. Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant 2009; 24: 919-925.
23. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773.
24. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549-1557.
25. Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 2002; 17(Suppl 1): 48-52.
26. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337.
27. Agarwal R, Davis JL, Smith L. Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 98-104.
28. Pollock C, Johnson DW, Horl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008; 3: 193-199.
29. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16(Suppl 3): 14-21.
30. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16(Suppl 7): 25-28.
31. Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009; 361: 1848-1855.
32. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78.
33. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-153.
34. Kilpatrick RD, Danese MD, Belozeroff V, Smirnakis K, Goodman WG, Rothman KJ. The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study. Pharmacoepidemiol Drug Saf 2011; 20: 914-921.
35. Koopmans PC, Bos JH, de Jong van den Berg LT. Are antibiotics related to oral combination contraceptive failures in the Netherlands? A case-crossover study. Pharmacoepidemiol Drug Saf 2012; 21: 865-871.
36. Orriols L, Wilchesky M, Lagarde E, Suissa S. Prescription of antidepressants and the risk of road traffic crash in the elderly: a case-crossover study. Br J Clin Pharmacol 2013; 76: 810-815.
37. Maclure M. 'Why me?' versus 'why now?'-differences between operational hypotheses in case-control versus case-crossover studies. Pharmacoepidemiol Drug Saf 2007; 16: 850-853.
38. de Francisco AL, Kim J, Anker SD, et al. An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: results of the ARO study. Nephron Clin Pract 2011; 118: c143-c154.
39. EMEA. Aranesp: EPAR - Product Information. 12/09/2013 Aranesp-EMEA/H/C/000332-IB/0114, 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000332/WC500026149.pdf [15 May 2014].
40. Kalicki RM, Uehlinger DE. Red cell survival in relation to changes in the hematocrit: more important than you think. Blood Purif 2008; 26: 355-360.
41. Spurling MC, Vinson DC. Alcohol-related injuries: evidence for the prevention paradox. Ann Fam Med 2005; 3: 47-52.
42. Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgens and erythropoiesis: past and present. J Endocrinol Invest 2009; 32: 704-716.
43. Di Iorio BR, Stellato D, De Santo NG, Cirillo M. Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status. Blood Purif 2004; 22: 423-427.
44. Stenvinkel P, Barany P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transplant 2002; 17(Suppl 5): 32-37.
45. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080.
46. Kapoian T, O'Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19: 372-379.
47. Locatelli F, Andrulli S, Memoli B, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 991-998.
48. Minutolo R, Conte G, Cianciaruso B, et al. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrol Dial Transplant 2012; 27: 2880-2886.
49. Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 2000; 37: 93-130.
50. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004; 15: 1877-1882.